Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Journal des Maladies...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Journal des Maladies Vasculaires
Article . 2015 . Peer-reviewed
License: Elsevier TDM
Data sources: Crossref
versions View all 3 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Prévention des évènements thromboemboliques veineux par fondaparinux 2,5mg chez des patients hospitalisés pour une affection médicale aiguë. Étude ArchiMed. ArchiMed hôpital – étude observationnelle d’usage du fondaparinux 2,5mg en vie réelle ; 718 patients inclus par 107 pharmaciens hospitaliers

Authors: Leroyer, C.; Mahé, I.; Daurès, J.-P.; Quéré, I.; Aubin, C.; Compagnon, A.; Doussaint, J.; +2 Authors

Prévention des évènements thromboemboliques veineux par fondaparinux 2,5mg chez des patients hospitalisés pour une affection médicale aiguë. Étude ArchiMed. ArchiMed hôpital – étude observationnelle d’usage du fondaparinux 2,5mg en vie réelle ; 718 patients inclus par 107 pharmaciens hospitaliers

Abstract

Resume Objectifs Evaluer la duree moyenne de traitement par fondaparinux 2,5 mg a l’hopital, dans son indication thromboprophylaxie en prevention medicale et decrire la population rejointe. Methode Etude epidemiologique prospective, observationnelle, nationale et multicentrique realisee a la demande de la Commission de la transparence, en complement du volet ville, precedemment mene en medecine generale. Dans le volet hopital, les pharmaciens hospitaliers devaient inclure les 15 premiers patients adultes, hospitalises (hors services de chirurgie), ayant l’instauration d’un traitement par fondaparinux 2,5 mg en thromboprophylaxie medicale. Resultats Cinquante-trois pharmaciens hospitaliers (49,5 %) ont inclus 718 patients âges de 71 ± 16 ans en moyenne (53 % > 75 ans) dont 54 % etaient des femmes. La duree totale reelle de traitement par fondaparinux 2,5 mg, etait en moyenne de 19,1 jours (min–max : 1–295 jours, mediane : 11 jours). Pour 41 % des patients, la duree totale de traitement etait comprise entre 6 et 14 jours. Quatre-vingt-cinq pour cent des patients avaient au moins une pathologie associee a la prescription d’un traitement par fondaparinux 2,5 mg. Dix pour cent des patients avaient au moins un facteur de risque renseigne par le medecin ou etaient âges de plus de 75 ans. La mise en perspective des caracteristiques des patients du volet hopital et du volet ville montre des differences de profil. Conclusion ArchiMed hopital, qui s’inscrit dans une categorie d’etudes qui s’apparente a des « audits de pratique », montre que la prescription du fondaparinux 2,5 mg en conditions reelles d’utilisation a l’hopital est globalement en adequation avec les recommandations pour l’indication de prevention en situation medicale aigue.

Country
France
Subjects by Vocabulary

Microsoft Academic Graph classification: Gynecology medicine.medical_specialty business.industry Fondaparinux Medical illness medicine In patient business medicine.drug

Keywords

[SDV]Life Sciences [q-bio], Drug utilization, Epidemiology, Hospitalization, Hôpital, Thrombose veineuse, Utilisation médicament, Venous thrombosis, Épidémiologie, Cardiology and Cardiovascular Medicine

18 references, page 1 of 2

[1] Benard E, Lafuma A, Ravaud P. Epidemiology of venous thromboembolic disease. Presse Med 2005 34=415-9. [OpenAIRE]

[2] Anderson Jr FA, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003 107(Suppl. 1) =I9-16.

[3] Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CM, Lassen MR, et al. Prevention of venous thromboembolism= American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008 133(Suppl.) = 381S-453S.

[4] Bergmann JF, Lloret-Linares C, Rami A, Cohen AT, Garay RP, Kakkar AK, et al. Venous thromboembolism risk and prophylaxis in the acute hospital care settiing (ENDORSE study) = results obtained in France. Presse Med 201 40=528-37.

[5] Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients = randomised placebo controlled trial. BMJ 2006 332=325-9.

[6] Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients= Antithrombotic Therapy and Prevention of Thrombosis, 9th ed= American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Chest 2012 141(Suppl.) =e195S-226S.

[7] Recommandations de bonne pratique. Prévention et traitement de la maladie thromboembolique veineuse en médecine. Agence de sécurité sanitaire des produits de santé 2009.

[8] Emmerich J. Frequency and risk factors of thrombo-embolic venous disease. Rev Prat 2003 53 =14-9.

[9] Rosendaal FR. Venous thrombosis= a multicausal disease. Lancet 1999 353 =167-73.

[10] Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999 341 =793-800. [OpenAIRE]

  • BIP!
    Impact byBIP!
    citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    1
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
  • citations
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    1
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
    Powered byBIP!BIP!
Powered by OpenAIRE graph
Found an issue? Give us feedback
citations
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
1
Average
Average
Average
bronze